Publicaciones en colaboración con investigadores/as de Memorial Sloan Kettering Cancer Center (18)

2023

  1. Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial

    The Lancet, Vol. 402, Núm. 10411, pp. 1423-1433

2022

  1. Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer

    Annals of Oncology, Vol. 33, Núm. 12, pp. 1250-1268

  2. Sacituzumab Govitecan in Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Metastatic Breast Cancer

    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Vol. 40, Núm. 29, pp. 3365-3376

2021

  1. Alpelisib plus fulvestrant in PIK3CA-mutated, hormone receptor-positive advanced breast cancer after a CDK4/6 inhibitor (BYLieve): one cohort of a phase 2, multicentre, open-label, non-comparative study

    The Lancet Oncology, Vol. 22, Núm. 4, pp. 489-498

  2. First Nationwide Molecular Screening Program in Spain for Patients With Advanced Breast Cancer: Results From the AGATA SOLTI-1301 Study

    Frontiers in Oncology, Vol. 11

  3. Genomic and transcriptomic analyses of breast cancer primaries and matched metastases in Aurora, the breast international group (Big) molecular screening initiative

    Cancer Discovery, Vol. 11, Núm. 11, pp. 2796-2811

2020

  1. Capivasertib, an AKT Kinase Inhibitor, as Monotherapy or in Combination with Fulvestrant in Patients with AKT1E17K-Mutant, ER-Positive Metastatic Breast Cancer

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 26, Núm. 15, pp. 3947-3957

  2. Phase 2 study of buparlisib (BKM120), a pan-class I PI3K inhibitor, in patients with metastatic triple-negative breast cancer

    Breast Cancer Research, Vol. 22, Núm. 1

2019

  1. Everolimus plus Exemestane for Hormone Receptor-Positive Advanced Breast Cancer: A PAM50 Intrinsic Subtype Analysis of BOLERO-2

    Oncologist, Vol. 24, Núm. 7, pp. 893-900

  2. Neoadjuvant letrozole plus taselisib versus letrozole plus placebo in postmenopausal women with oestrogen receptor-positive, HER2-negative, early-stage breast cancer (LORELEI): a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial

    The Lancet Oncology, Vol. 20, Núm. 9, pp. 1226-1238

2018

  1. Primary results of the first nationwide molecular screening program in Spain for patients with advanced breast cancer (AGATA SOLTI-1301 study)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 29, pp. viii90

  2. Reply to 'the St Gallen international expert consensus on the primary therapy of early breast cancer 2017: Te point of view of an international panel of experts in radiation oncology' by Kirova et al.

    Annals of Oncology

2017

  1. A phase II study of combined ridaforolimus and dalotuzumab compared with exemestane in patients with estrogen receptor-positive breast cancer

    Breast Cancer Research and Treatment, Vol. 163, Núm. 3, pp. 535-544

  2. De-escalating and escalating treatments for early-stage breast cancer: The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1700-1712

2015

  1. Pertuzumab, trastuzumab, and docetaxel in HER2-positive metastatic breast cancer

    New England Journal of Medicine, Vol. 372, Núm. 8, pp. 724-734

2014

  1. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): Follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort

    The Lancet Oncology, Vol. 15, Núm. 6, pp. 640-647

2013

  1. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): Overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study

    The Lancet Oncology, Vol. 14, Núm. 6, pp. 461-471

  2. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer

    Journal of Clinical Oncology, Vol. 31, Núm. 20, pp. 2586-2592